CRISPR Therapeutics AG (CRSP) Current Assets (2015 - 2026)

CRISPR Therapeutics AG (CRSP) has 12 years of Current Assets data on file, last reported at $2.4 billion in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 31.1% year-over-year to $2.4 billion; the trailing twelve-month figure through Mar 2026 stood at $2.4 billion (up 31.1% YoY), and the FY2025 full-year result was $2.0 billion, up 2.51% from the prior year.
• Current Assets advanced to $2.4 billion in Q1 2026, from $2.0 billion in the prior quarter.
• In the past five years, Current Assets ranged from a high of $2.4 billion in Q1 2026 to a low of $1.7 billion in Q2 2025.
• A 5-year average of $2.0 billion and a median of $1.9 billion in 2022 frame the typical range for Current Assets.
• Across the five-year window, Current Assets decreased 23.35% in 2022 and soared 31.1% in 2026, its largest moves.
• Tracing CRSP's Current Assets over 5 years: stood at $1.9 billion in 2022, then advanced by 2.97% to $1.9 billion in 2023, then gained by 1.52% to $1.9 billion in 2024, then gained by 2.51% to $2.0 billion in 2025, then rose by 23.3% to $2.4 billion in 2026.
• Business Quant data shows CRSP's Current Assets at $2.4 billion in Q1 2026, $2.0 billion in Q4 2025, and $1.9 billion in Q3 2025.